Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Harvard Business School
Medtronic
Moodys
Colorcon

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

Litigation Details for ViiV Healthcare UK Ltd. v. Lupin Ltd. (D. Del. 2011)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

ViiV Healthcare UK Ltd. v. Lupin Ltd. (D. Del. 2011)

Docket   Start Trial Date Filed 2011-06-29
Court District Court, D. Delaware Date Terminated 2014-01-24
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand Defendant Referred To
Parties LUPIN LTD.; LUPIN PHARMACEUTICALS INC.; TEVA PHARMACEUTICALS USA INC.; VIIV HEALTHCARE CO.; VIIV HEALTHCARE UK LTD.
Patents 6,417,191
Attorneys Annemarie Hassett; Brian E. Farnan; Charles A. Fernandez; Craig T. Murray; David Ellis Moore; David M. Hashmall; Deanne M. Mazzochi; Eric H. Yecies; F. Christopher Mizzo; Gregory T. Sandidge; Harven DeShield; Ira J. Levy; John C. Phillips , Jr.; Joseph J. Farnan , Jr.; Joshua A. Whitehill; Lauren M. Nowierski; Matthew T. Lord; Megan C. Haney; Natasha E. Daughtrey; Neil A. Benchell; Paul J. Molino; Richard L. Horwitz; Rivka Jungreis; Tara M. Raghavan; William A. Rakoczy; Yixin H. Tang
Link to Docket External link to docket
Small Molecule Drugs cited in ViiV Healthcare UK Ltd. v. Lupin Ltd.
The small molecule drugs covered by the patent cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for ViiV Healthcare UK Ltd. v. Lupin Ltd. (D. Del. 2011)

Date Filed Document No. Description Snippet Link To Document
2011-06-29 1 United States Patent No. 6,417,191 (“the ‘l9l patent”). This action is based upon the Patent Laws of the…§ l39l(b) and (c), and l400(b). THE PATENT 13. The ‘191 patent, entitled “Synergistic Combinations of…the ‘191 patent including the right to sue and to recover for any infringement of that patent, A true …during the term of the ‘191 patent, it would further infringe that patent under 35 U.S.C. § 271(a), (b…during the term of the ‘191 patent, it would further infringe the ‘191 patent under 35 U.S.C. § 271(a), External link to document
2012-11-16 126 Healthcare Co. assert U.S. Patent No. 6,417,191 ('" 191 Patent") against Defendants Lupin… Teva Pharmaceuticals, USA, Inc. 1 The '191 Patent relates to therapeutic combinations of anti-HIV… Construction Construction from Patent-in-Suit "(IS, 4R)- Plain and… Construction Construction Patent-in-Suit "combination" Plain… Construction Construction Patent-in-Suit "pharmaceutical Plain and External link to document
2013-12-17 257 ViiV") assert U.S. Patent No. 6,417,191 (''the' 191 Patent") against Defendants… '191 Patent is invalid as obvious. Lupin individually asserts that the '191 Patent is invalid…ofblocking patents. 38 Defendants main argument is that the existence of"blocking patents," owned… some appeal if the patent claims did not limit the term animal, here the patent claims explicitly limit…that the '161 Patent is not sufficiently enabled for a POSA to utilize the patent without undue experimentation External link to document
2014-01-28 276 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,417,191. (Attachments: # 1 …2011 24 January 2014 1:11-cv-00576-RGA Patent Defendant District Court, D. External link to document
2011-06-29 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,417,191;. (dzs, ) (Entered:…2011 24 January 2014 1:11-cv-00576-RGA Patent Defendant District Court, D. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Boehringer Ingelheim
Dow
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.